Literature DB >> 17357148

Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese.

Norio Yasui-Furukori1, Ayako Kaneda, Kumiko Iwashima, Manabu Saito, Taku Nakagami, Shoko Tsuchimine, Sunao Kaneko.   

Abstract

Polymorphic enzyme cytochrome P450 (CYP) 2C19 is expressed not only in the liver but also in the brain and mediates the biotransformation of 5-hydroxytriptamine (5-HT). We investigated possible association between genetic polymorphism of CYP2C19 and individual personality traits, possibly influenced by neurotransmitters. Mentally and physically healthy Japanese subjects were enrolled in this study (n = 352). Temperament and Character Inventory (TCI) and CYP2C19 genotyping were performed in all subjects. We detected CYP2C19*2 and *3 (http://www.imm.ki.se/CYPalleles/) using Amplichip CYP450 DNA tip. The number of genotypes classified as homozygous extensive metabolizer (EM), heterozygous EM, and poor metabolizer were 113, 181, and 58, respectively. Significant difference was found in TCI score in harm avoidance (HA; F = 3.138, P < 0.05). Post hoc analysis showed that TCI score in harm avoidance in homozygous EM was significantly lower than that in heterozygous EM (P < 0.05) or PM (P < 0.05). In sub-item analyses, HA3 (shyness with strangers, P < 0.01) and HA1 (anticipatory worry, P < 0.05) of TCI scores were significantly different among CYP2C19 genotypes. Meanwhile, there were no differences in TCI scores of novelty seeking (NS; F = 0.350, n.s.), reward dependence (RD; F = 1.080, n.s.), or persistence (P; F = 0.786, n.s.) among CYP2C19 genotypes. This study demonstrated that a significant association between CYP2C19 activity and HA is present in Japanese. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357148     DOI: 10.1002/ajmg.b.30430

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  6 in total

1.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 2.  Sex steroid-related candidate genes in psychiatric disorders.

Authors:  Lars Westberg; Elias Eriksson
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

3.  Melatonin metabolism in the central nervous system.

Authors:  Rüdiger Hardeland
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 4.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Authors:  Junji Saruwatari; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-20

Review 5.  Taxon- and Site-Specific Melatonin Catabolism.

Authors:  Rüdiger Hardeland
Journal:  Molecules       Date:  2017-11-21       Impact factor: 4.411

6.  Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene.

Authors:  A Persson; S C Sim; S Virding; N Onishchenko; G Schulte; M Ingelman-Sundberg
Journal:  Mol Psychiatry       Date:  2013-07-23       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.